Status:
COMPLETED
Block-replacement Therapy During Radioiodine Therapy
Lead Sponsor:
Steen Bonnema
Conditions:
Toxic Nodular Goitre
Graves' Disease
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Background: The use of radioactive iodine (131I) therapy as the definite cure of hyperthyroidism is widespread. According to a survey on the management of Graves' disease, thirty per cent of physician...
Eligibility Criteria
Inclusion
- Hyperthyroid patients going to be treated with radioiodine either due to recurrent Graves' disease or toxic nodular goiter.
Exclusion
- Age \< 18 yrs.
- Allergy to anti-thyroid drugs
- Substernal or large (\> 100ml) goiter
- Severe endocrine ophthalmopathy
- Pregnancy or lactation
- Suspicion of thyroid malignancy
- Unsafe contra-conception
- Physical or mental condition that hinders corporation
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00150124
Start Date
January 1 2003
End Date
March 1 2009
Last Update
December 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, Odense University Hospital
Odense, Funen, Denmark, 5000